Loading
A phase 1/2 trial of Capecitabine, Oxaliplatin, Penpulimab and Tislelizumab in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Clinical Studies for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06825494 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 194 participants planned, started 2025-04-08 and due to reach its primary completion in 2026-03. Interventions recorded: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab and enpulimab+ Oxaliplatin+Capecitabine.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Penpulimab, Sino Biopharmaceutical (Chia Tai Tianqing), Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Immune checkpoint inhibitors and the tag pipeline.